Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Short-course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania.

Katende A, Mbwanji G, Faini D, Nyuri A, Kalinjuma AV, Mnzava D, Hullsiek KH, Rhein J, Weisser M, Meya DB, Boulware DR, Letang E; KIULARCO Study Group.

Mycoses. 2019 Dec;62(12):1127-1132. doi: 10.1111/myc.12995. Epub 2019 Oct 21.

PMID:
31461550
2.

Management of amphotericin-induced phlebitis among HIV patients with cryptococcal meningitis in a resource-limited setting: a prospective cohort study.

Ahimbisibwe C, Kwizera R, Ndyetukira JF, Kugonza F, Sadiq A, Hullsiek KH, Williams DA, Rhein J, Boulware DR, Meya DB.

BMC Infect Dis. 2019 Jun 26;19(1):558. doi: 10.1186/s12879-019-4209-7.

3.

The Effects of Recombinant Human Lactoferrin on Immune Activation and the Intestinal Microbiome Among Persons Living with Human Immunodeficiency Virus and Receiving Antiretroviral Therapy.

Sortino O, Hullsiek KH, Richards E, Rupert A, Schminke A, Tetekpor N, Quinones M, Prosser R, Schacker T, Sereti I, Baker JV.

J Infect Dis. 2019 May 24;219(12):1963-1968. doi: 10.1093/infdis/jiz042.

PMID:
30721997
4.

Blood neutrophil counts in HIV-infected patients with cryptococcal meningitis: Association with mortality.

Musubire AK, Meya DB, Rhein J, Meintjes G, Bohjanen PR, Nuwagira E, Muzoora C, Boulware DR, Hullsiek KH; COAT and ASTRO trial teams.

PLoS One. 2018 Dec 31;13(12):e0209337. doi: 10.1371/journal.pone.0209337. eCollection 2018.

5.

HIV-Associated Cryptococcal Meningitis Occurring at Relatively Higher CD4 Counts.

Tugume L, Rhein J, Hullsiek KH, Mpoza E, Kiggundu R, Ssebambulidde K, Schutz C, Taseera K, Williams DA, Abassi M, Muzoora C, Musubire AK, Meintjes G, Meya DB, Boulware DR; COAT and ASTRO-CM teams .

J Infect Dis. 2019 Feb 23;219(6):877-883. doi: 10.1093/infdis/jiy602.

PMID:
30325463
6.

Symptomatic Cryptococcal Antigenemia Presenting as Early Cryptococcal Meningitis With Negative Cerebral Spinal Fluid Analysis.

Ssebambulidde K, Bangdiwala AS, Kwizera R, Kandole TK, Tugume L, Kiggundu R, Mpoza E, Nuwagira E, Williams DA, Lofgren SM, Abassi M, Musubire AK, Cresswell FV, Rhein J, Muzoora C, Hullsiek KH, Boulware DR, Meya DB; Adjunctive Sertraline for Treatment of HIV-associated Cryptococcal Meningitis Team .

Clin Infect Dis. 2019 May 30;68(12):2094-2098. doi: 10.1093/cid/ciy817.

7.

Detrimental Outcomes of Unmasking Cryptococcal Meningitis With Recent ART Initiation.

Rhein J, Hullsiek KH, Evans EE, Tugume L, Nuwagira E, Ssebambulidde K, Kiggundu R, Mpoza E, Musubire AK, Bangdiwala AS, Bahr NC, Williams DA, Abassi M, Muzoora C, Meya DB, Boulware DR; ASTRO-CM study team .

Open Forum Infect Dis. 2018 May 24;5(8):ofy122. doi: 10.1093/ofid/ofy122. eCollection 2018 Aug.

8.

Cerebral Oximetry for Detecting High-mortality Risk Patients with Cryptococcal Meningitis.

Diehl JW, Hullsiek KH, Okirwoth M, Stephens N, Abassi M, Rhein J, Meya DB, Boulware DR, Musubire AK; ASTRO-CM Trial Team .

Open Forum Infect Dis. 2018 May 8;5(6):ofy105. doi: 10.1093/ofid/ofy105. eCollection 2018 Jun 1.

9.

Evolving Failures in the Delivery of Human Immunodeficiency Virus Care: Lessons From a Ugandan Meningitis Cohort 2006-2016.

Flynn AG, Meya DB, Hullsiek KH, Rhein J, Williams DA, Musubire A, Morawski BM, Taseera K, Sadiq A, Ndyatunga L, Roediger M, Rajasingham R, Bohjanen PR, Muzoora C, Boulware DR.

Open Forum Infect Dis. 2017 Apr 19;4(2):ofx077. doi: 10.1093/ofid/ofx077. eCollection 2017 Spring.

10.

Vitamin D deficiency is associated with IL-6 levels and monocyte activation in HIV-infected persons.

Manion M, Hullsiek KH, Wilson EMP, Rhame F, Kojic E, Gibson D, Hammer J, Patel P, Brooks JT, Baker JV, Sereti I; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Antiretroviral Therapy (the ‘SUN Study’) Investigators.

PLoS One. 2017 May 2;12(5):e0175517. doi: 10.1371/journal.pone.0175517. eCollection 2017.

11.

Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.

Lofgren S, Hullsiek KH, Morawski BM, Nabeta HW, Kiggundu R, Taseera K, Musubire A, Schutz C, Abassi M, Bahr NC, Tugume L, Muzoora C, Williams DA, Rolfes MA, Velamakanni SS, Rajasingham R, Meintjes G, Rhein J, Meya DB, Boulware DR; COAT and ASTRO-CM Trial Teams.

J Infect Dis. 2017 Mar 1;215(5):693-697. doi: 10.1093/infdis/jix033.

12.

Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial.

Baker JV, Hullsiek KH, Engen NW, Nelson R, Chetchotisakd P, Gerstoft J, Jessen H, Losso M, Markowitz N, Munderi P, Papadopoulos A, Shuter J, Rappoport C, Pearson MT, Finley E, Babiker A, Emery S, Duprez D; INSIGHT START Arterial Elasticity Substudy Team.

Open Forum Infect Dis. 2016 Oct 8;3(4):ofw213. eCollection 2016 Oct.

13.

Prognostic implications of baseline anaemia and changes in haemoglobin concentrations with amphotericin B therapy for cryptococcal meningitis.

Tugume L, Morawski BM, Abassi M, Bahr NC, Kiggundu R, Nabeta HW, Hullsiek KH, Taseera K, Musubire AK, Schutz C, Muzoora C, Williams DA, Rolfes MA, Meintjes G, Rhein J, Meya DB, Boulware DR.

HIV Med. 2017 Jan;18(1):13-20. doi: 10.1111/hiv.12387. Epub 2016 Apr 28.

14.

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.

Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L, Musubire A, Akampurira A, Smith KD, Alhadab A, Williams DA, Abassi M, Bahr NC, Velamakanni SS, Fisher J, Nielsen K, Meya DB, Boulware DR; ASTRO-CM Study Team.

Lancet Infect Dis. 2016 Jul;16(7):809-818. doi: 10.1016/S1473-3099(16)00074-8. Epub 2016 Mar 10.

15.

Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis.

Kiggundu R, Morawski BM, Bahr NC, Rhein J, Musubire AK, Williams DA, Abassi M, Nabeta HW, Hullsiek KH, Meya DB, Boulware DR; ASTRO-CM Team.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):65-9. doi: 10.1097/QAI.0000000000000812.

16.

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.

Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki LH, Alhadab AA, Akampurira A, Rhein JR, Meya DB, Boulware DR, Nielsen K; ASTRO-CM/COAT Team.

Antimicrob Agents Chemother. 2015 Dec;59(12):7197-204. doi: 10.1128/AAC.01299-15. Epub 2015 Aug 31.

17.

INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy.

Hullsiek KH, Kagan JM, Engen N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH.

Ther Innov Regul Sci. 2015 Mar 1;49(2):225-233.

18.

Response to Bandera et al.

Wilson EM, Hullsiek KH, Sereti I, Baker JV.

J Infect Dis. 2015 Sep 1;212(5):841-2. doi: 10.1093/infdis/jiv165. Epub 2015 Mar 19. No abstract available.

19.

Early ART After Cryptococcal Meningitis Is Associated With Cerebrospinal Fluid Pleocytosis and Macrophage Activation in a Multisite Randomized Trial.

Scriven JE, Rhein J, Hullsiek KH, von Hohenberg M, Linder G, Rolfes MA, Williams DA, Taseera K, Meya DB, Meintjes G, Boulware DR; COAT Team.

J Infect Dis. 2015 Sep 1;212(5):769-78. doi: 10.1093/infdis/jiv067. Epub 2015 Feb 4.

20.

The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.

Rolfes MA, Hullsiek KH, Rhein J, Nabeta HW, Taseera K, Schutz C, Musubire A, Rajasingham R, Williams DA, Thienemann F, Muzoora C, Meintjes G, Meya DB, Boulware DR.

Clin Infect Dis. 2014 Dec 1;59(11):1607-14. doi: 10.1093/cid/ciu596. Epub 2014 Jul 23. Erratum in: Clin Infect Dis. 2015 May 1;60(9):1449.

21.

Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.

Wilson EM, Singh A, Hullsiek KH, Gibson D, Henry WK, Lichtenstein K, Önen NF, Kojic E, Patel P, Brooks JT, Sereti I, Baker JV; Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study) Investigators.

J Infect Dis. 2014 Nov 1;210(9):1396-406. doi: 10.1093/infdis/jiu275. Epub 2014 May 9.

22.

Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort.

Baker JV, Hullsiek KH, Singh A, Wilson E, Henry K, Lichtenstein K, Onen N, Kojic E, Patel P, Brooks JT, Hodis HN, Budoff M, Sereti I; CDC SUN Study Investigators.

AIDS. 2014 Mar 27;28(6):831-40. doi: 10.1097/QAD.0000000000000145.

23.

Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses.

Andrade BB, Hullsiek KH, Boulware DR, Rupert A, French MA, Ruxrungtham K, Montes ML, Price H, Barreiro P, Audsley J, Sher A, Lewin SR, Sereti I; INSIGHT Study Group.

J Infect Dis. 2013 May 1;207(9):1379-88. doi: 10.1093/infdis/jit033. Epub 2013 Jan 18.

24.

Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Kozal MJ, Svarovskaia ES, Johnson JA, Geretti AM, Metzner KJ, Jakobsen MR, Hullsiek KH, Ostergaard L, Miller MD, Kuritzkes DR.

J Infect Dis. 2013 Mar 15;207(6):893-7. doi: 10.1093/infdis/jis925. Epub 2012 Dec 21.

25.

Hepatitis B vaccine antibody response and the risk of clinical AIDS or death.

Landrum ML, Hullsiek KH, O'Connell RJ, Chun HM, Ganesan A, Okulicz JF, Lalani T, Weintrob AC, Crum-Cianflone NF, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

PLoS One. 2012;7(3):e33488. doi: 10.1371/journal.pone.0033488. Epub 2012 Mar 22.

26.

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Kozal MJ, Hullsiek KH, Miller MD, Bangsberg DR, Kuritzkes DR.

AIDS. 2012 Jan 14;26(2):185-92. doi: 10.1097/QAD.0b013e32834e9d7d. Review.

27.

Considerations for Endpoint Selection When Designing HIV Clinical Trials.

Hullsiek KH, Grund B.

Curr Infect Dis Rep. 2012 Feb;14(1):110-8. doi: 10.1007/s11908-011-0231-7.

PMID:
22161272
28.

Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters.

Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML; Infectious Disease Clinical Research Program HIV Working Group.

J Infect Dis. 2012 Jan 15;205(2):185-93. doi: 10.1093/infdis/jir720. Epub 2011 Dec 5.

29.

Elevated CD8 counts during HAART are associated with HIV virologic treatment failure.

Krantz EM, Hullsiek KH, Okulicz JF, Weintrob AC, Agan BK, Crum-Cianflone NF, Ganesan A, Ferguson TM, Hale BR; Infectious Disease Clinical Research Program HIV Working Group.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):396-403. doi: 10.1097/QAI.0b013e318221c62a.

30.

Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death.

Boulware DR, Hullsiek KH, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I; INSIGHT Study Group.

J Infect Dis. 2011 Jun 1;203(11):1637-46. doi: 10.1093/infdis/jir134.

31.

Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.

Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, Kozal MJ, Hullsiek KH, Balduin M, Jakobsen MR, Geretti AM, Thiebaut R, Ostergaard L, Masquelier B, Johnson JA, Miller MD, Kuritzkes DR.

JAMA. 2011 Apr 6;305(13):1327-35. doi: 10.1001/jama.2011.375. Review.

32.

The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis.

Landrum ML, Hullsiek KH, Chun HM, Crum-Cianflone NF, Ganesan A, Weintrob AC, Barthel RV, O'Connell RJ, Agan BK.

Am J Epidemiol. 2011 Jan 1;173(1):84-93. doi: 10.1093/aje/kwq326. Epub 2010 Nov 4.

33.

Designing and managing a flexible and dynamic biorepository system: a 15-year perspective from the CPCRA, ESPRIT, and INSIGHT clinical trial networks.

Hullsiek KH, George M, Brown SK.

Curr Opin HIV AIDS. 2010 Nov;5(6):538-44. doi: 10.1097/COH.0b013e32833f2058. Review.

34.

Is Kaposi's sarcoma occurring at higher CD4 cell counts over the course of the HIV epidemic?

Crum-Cianflone NF, Hullsiek KH, Ganesan A, Weintrob A, Okulicz JF, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

AIDS. 2010 Nov 27;24(18):2881-3. doi: 10.1097/QAD.0b013e32833f9fb8.

35.

Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection.

Baker J, Quick H, Hullsiek KH, Tracy R, Duprez D, Henry K, Neaton JD.

HIV Med. 2010 Oct 1;11(9):608-9. doi: 10.1111/j.1468-1293.2010.00835.x. Epub 2010 Jun 28. No abstract available.

36.

Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.

Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB; Terry Beirn Community Programs for Clinical Research on AIDS and the International Network for Strategic Initiatives in Global HIV Trials.

AIDS. 2010 Jan 28;24(3):395-403.

37.

Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years.

Chun HM, Fieberg AM, Hullsiek KH, Lifson AR, Crum-Cianflone NF, Weintrob AC, Ganesan A, Barthel RV, Bradley WP, Agan BK, Landrum ML; Infectious Disease Clinical Research Program HIV Working Group.

Clin Infect Dis. 2010 Feb 1;50(3):426-36. doi: 10.1086/649885.

38.

High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, Duprez D, Neaton JD.

J Infect Dis. 2010 Jan 15;201(2):285-92. doi: 10.1086/649560.

39.

Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.

Crum-Cianflone NF, Hullsiek KH, Marconi VC, Ganesan A, Weintrob A, Barthel RV, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

AIDS. 2010 Feb 20;24(4):535-43. doi: 10.1097/QAD.0b013e328331f6e2.

40.

Untreated HIV infection and large and small artery elasticity.

Baker JV, Duprez D, Rapkin J, Hullsiek KH, Quick H, Grimm R, Neaton JD, Henry K.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):25-31.

41.

Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: authors' reply.

Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK.

AIDS. 2009 Aug 24;23(13):1791-2. doi: 10.1097/QAD.0b013e32832cb296. No abstract available.

PMID:
19684484
42.

Cutaneous malignancies among HIV-infected persons.

Crum-Cianflone N, Hullsiek KH, Satter E, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK.

Arch Intern Med. 2009 Jun 22;169(12):1130-8. doi: 10.1001/archinternmed.2009.104.

43.

Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals.

Landrum ML, Hullsiek KH, Ganesan A, Weintrob AC, Crum-Cianflone NF, Barthel RV, O'Connell RJ, Fieberg A, Chun HM, Marconi VC, Dolan MJ, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

AIDS. 2010 Feb 20;24(4):545-55. doi: 10.1097/QAD.0b013e32832cd99e.

44.

The impact of nelfinavir exposure on cancer development among a large cohort of HIV-infected patients.

Crum-Cianflone NF, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Roediger MP, Agan B, Wegner S.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):305-9. doi: 10.1097/QAI.0b013e3181aa13c7.

45.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

PMID:
19210162
46.

Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.

Crum-Cianflone N, Hullsiek KH, Marconi V, Weintrob A, Ganesan A, Barthel RV, Fraser S, Agan BK, Wegner S.

AIDS. 2009 Jan 2;23(1):41-50. doi: 10.1097/QAD.0b013e328317cc2d.

47.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

48.

Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.

van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT).

HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324.

PMID:
18977721
49.

Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance.

Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB.

AIDS. 2008 Jan 2;22(1):75-82.

50.

The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.

Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

HIV Clin Trials. 2007 Nov-Dec;8(6):357-70.

PMID:
18042501

Supplemental Content

Loading ...
Support Center